Purpose: To report 5 cases of culture-proven fungal keratitis that resolved with moxifloxacin monotherapy.
T raditionally, antibacterial agents have been considered to have no significant therapeutic effect against fungal pathogens. In fact, antibacterial agents are routinely used to supplement fungal culture media to enhance recovery of fungi. In the past, reports of cure of fungal keratitis by antibiotic therapy have been rare. 1, 2 In recent years, however, a number of cases of Fusarium keratitis have been reported to have responded to topical antibiotic therapy. [3] [4] [5] This report describes 5 cases of fungal keratitis cured with single-agent therapy with topical moxifloxacin 0.5%.
CASE REPORTS

Case 1
A 49-year-old man was referred with a 15-day history of foreign body sensation OS that developed while he was working in the yard.
Visual acuity was 20/25. There was a 1.5-mm dense anterior stromal infiltrate in the inferotemporal quadrant. Routine and fungal cultures were obtained and the patient was treated with moxifloxacin 0.5%, 1 drop every hour pending culture results. Monotherapy with a fluoroquinolone agent was initially used because the infiltrate was small and the course had been indolent. The patient did not keep his next appointment. On day 3, a mold was identified in the culture. The patient was contacted and finally returned 5 days after the first visit. By the time of his return visit, his condition improved. The pain had resolved and the infiltrate was less dense. Moxifloxacin therapy was continued and the infection resolved over 2 weeks. The organism was identified as Curvularia spp. No other organisms were isolated. Final visual acuity was 20/20.
Case 2
A 52-year-old man presented with a 2-day history of severe pain in the left eye. He had experienced a metallic foreign body injury 3 weeks previously, with persistent sensation of the foreign body that had worsened. Visual acuity was 20/30. A 2-mm irregularly shaped anterior stromal infiltrate with an overlying epithelial defect was present in the midperiphery at 3 o'clock. There was little surrounding inflammation. The appearance was suggestive of an indolent organism, such as fungus. Routine and fungal cultures were taken and moxifloxacin 0.5%, 1 drop every half hour was prescribed pending culture results. The fluoroquinolone was selected based on experience with case 1.
One day later, the infiltrate had begun to epithelialize, and the pain had decreased. By day 5, the infiltrate had decreased in area and density. The culture was reported to be positive for mold. Because the patient was doing well, treatment was continued with close follow-up. The infection resolved over the next 2 weeks. Final visual acuity was 20/20. The mold was identified as Curvularia spp. No other organisms were isolated.
Case 3
A 79-year-old man with non-insulin-dependent diabetes mellitus and a history of 3 previous penetrating keratoplasties in the left eye, originally for the indication of bullous keratopathy, was referred with a 1-month history of gradually worsening pain. The patient had seen his local ophthalmologist 1 day previously. At the time of his initial visit, he was using no topical medication OS.
Visual acuity was count fingers at 4 feet. The left cornea had an edematous graft with a 4-mm-diameter arcuate anterior stromal infiltrate, with finger-like spokes, many of which had a slightly crystalline appearance, extending into the surrounding stroma ( Fig. 1 ).
Cultures were taken and he was initially treated with ceftazidime 50 mg/mL 1 drop every hour pending culture results. On day 3, cultures grew yeast. At that time, the patient had no significant improvement. A prescription for natamycin was given, but the patient stated that he could not afford the medication. He was directed to go to the county general hospital to obtain the natamycin. In the meantime, a sample of moxifloxacin 0.5% was given to be used 1 drop every hour.
The patient returned 3 days later, having never obtained natamycin. He stated that he was feeling more comfortable. The infiltrate had begun to respond. Moxifloxacin 0.5% was continued. By the third week of treatment, the infiltrate had resolved. The yeast was identified as Candida parapsilosis. No other organisms were isolated.
Case 4
A 40-year-old woman who was a daily-wear soft contact lens wearer developed a 1-week history of increasing pain OD. She was seen by her local ophthalmologist and treated with tobramycin 14 mg/mL and gatifloxacin 0.3%, each 1 drop every hour, and referred after 2 days with no improvement.
Visual acuity was 20/60 OD. A 1.8-mm anterior stromal infiltrate was present near the visual axis. There were numerous small satellite infiltrates radiating from the central infiltrate ( Fig. 2 ). Routine and fungal cultures were taken and the patient was treated with moxifloxacin 0.5% 1 drop every half hour pending culture results.
After 1 day, the infiltrate had improved and the pain decreased. After 3 days, growth of mold was noted. The patient continued to improve, so moxifloxacin 0.5% was continued. After 2 weeks, the infiltrate appeared inactive. Moxifloxacin 0.5% was tapered and discontinued over an additional 2 weeks. The mold was identified as Paecilomyces lilacinum. No other organisms were isolated.
Case 5
A 21-year-old man was referred with an infiltrate of the right eye. He had a history of soft contact lens wear and had used a "no rub" contact lens solution. He had been under treatment for microbial keratitis for 3 weeks, which was gradually worsening. At the time of his initial visit, he was using ceftazidime 50 mg/mL and vancomycin 25 mg/mL, 1 drop every half hour. A culture performed 2 weeks previously had shown no growth.
Visual acuity was 200 E at 6 feet. Slit-lamp evaluation revealed a white chalky plaque measuring 7.5 mm by 3 mm covering the inferior cornea. A stromal infiltrate was present beneath the plaque (Fig. 3 ). Finger-like projections extended into the surrounding stroma. Routine and fungal cultures were taken and the patient was initially treated with moxifloxacin 0.5% solution, 1 drop every half hour pending culture results.
By day 4, when cultures grew mold, the infiltrate was less dense and the edges were more sharply demarcated. The pain had decreased, and visual acuity had improved to 20/400. Because the patient was improving, moxifloxacin 0.5% was continued with close follow-up. Moxifloxacin 0.5% was tapered to discontinuation over 6 weeks, during the course of which the plaque sloughed off. Final visual acuity was 20/50 with spectacle correction. The fungus was identified as Aspergillus flavus. No other organisms were isolated.
DISCUSSION
Antibiotics that have been reported to have antifungal efficacy are primarily aminoglycoside and fluoroquinolone agents. In 1975, Forster et al 1 reported that 2 patients from their series of 16 subjects with corneal culture-proven fungal keratitis were cured with topical gentamicin therapy. The etiologic agents were Curvularia pallescens and Drechslera halodes. The one patient for whom follow-up was available achieved best-corrected visual acuity of 20/50. The authors did not note the severity of the original infection.
Chodosh et al 2 reported cure of Fusarium oxysporum keratitis with topical tobramycin 14 mg/mL and vancomycin 50 mg/mL. The visual acuity improved from hand motions to 20/30. In vitro, the isolate was inhibited by tobramycin at a concentration of 0.45 mg/mL and higher, but vancomycin had no inhibitory effect.
More recently, Munir et al 4 reported 5 cases of fungal keratitis responsive to antibiotic therapy. Two cases were cured with moxifloxacin monotherapy. However, both cases were negative for corneal culture. In one case, Bipolaris species was isolated from the contact lens case, and the confocal microscopy was positive for hyphae. In the second case, Fusarium species grew in the contact lens case. It was not noted as to whether confocal microscopy was performed on this case. Corneal culture was positive for Staphylococcus epidermidis and Lactobacillus species in the third patient. Both types of bacteria plus Fusarium grew in the contact lens culture. The patient was cured with gatifloxacin 0.3% monotherapy. Of the 2 patients who had positive corneal cultures, both cultures grew Fusarium. In 1 case, the patient was cured by therapy with tobramycin 14 mg/mL and cefazolin 50 mg/mL, whereas the second patient initially responded to moxifloxacin but relapsed and required natamycin to effect a cure. The antibacterial activity of fluoroquinolone agents is largely due to their inhibitory effect on bacterial topoisomerase. 6 Many fungal pathogens have been noted to have high levels of topoisomerase, 7, 8 and it has been noted that quinolones are capable of binding fungal topoisomerase, 7,8 suggesting a mechanism of potential antifungal effect. In a study of 21 ocular isolates of Candida, Ozdek et al 9 found that both moxifloxacin and gatifloxacin demonstrated antifungal activity. At undiluted concentrations, .99.9% of growth was inhibited at day 1 by both drugs. There was no significant difference between the 2 drugs at full concentration. However, at diluted concentrations, gatifloxacin demonstrated more effect than moxifloxacin.
Day et al 10 tested the activity of amoxicillin, cefazolin, chloramphenicol, moxifloxacin, tobramycin, and benzalkonium chloride against ocular isolates of Fusarium spp. and A. flavus. Ten isolates of each organism were tested. The MIC 90 of tobramycin and moxifloxacin against Fusarium was 700 and 2000 mg/mL, respectively. The drugs did not inhibit Aspergillus. The MIC 90 of chloramphenicol for Fusarium was 2000 and 4000 mg/mL for Aspergillus. The other antibiotics demonstrated no antifungal activity. In contrast, the MIC 90 of benzalkonium chloride for Fusarium and Aspergillus was 64 and 16 mg/mL, respectively.
Other investigators have studied the interaction of quinolone and antifungal agents. Stergiopoulou et al 11 demonstrated that ciprofloxacin, which had no intrinsic antifungal activity, had significant interaction with antifungal agents to potentiate their activity against Candida albicans and A. fumigatus. Other investigators found variable interactions. Nakajima et al 12 demonstrated that DU-6859a, an investigational fluoroquinolone agent, enhanced the in vitro antifungal activity of amphotericin B (AmB) against C. albicans, Candida tropicalis, Candida krusei, Candida glabrata, and Cryptococcus neoformans; by itself, it had no antifungal activity. However, for Aspergillus fumigatus, the effect varied with the medium, with antagonistic interactions found in RPMI 1640. In animal studies, the agents prolonged the survival of mice infected with C. albicans, when administered in combination with AmB. Other authors have demonstrated concentration-dependent interactions with additive effect in some cases and antagonism in others. 13, 14 In the present series, 5 patients with fungal keratitis documented by positive corneal cultures had resolution of infection with moxifloxacin 0.5% monotherapy. The organisms killed include Curvularia spp., A. flavus, Candida parapsilosis, and Paecilomyces lilacinum. These cases expand the potential antifungal spectrum of fluoroquinolone agents.
These cases are reported to suggest that further studies to identify ways in which fluoroquinolone drugs may be used to enhance antifungal therapy may be productive. However, extreme caution should be utilized in the interpretation of the clinical implications. The experience of Khor et al 3 who found in their large series that only 16% of their cases responded to antibiotic therapy suggests that the vast majority of patients with fungal keratitis require specific antifungal therapy to obtain a favorable outcome.
The current cases were managed before the availability of confocal microscopy at our institution. Smears were either negative (3/5) or not obtained (2/5). In 2 cases, the clinical history and appearance were compatible with bacterial keratitis. In 3 cases, features suggestive of fungal keratitis were present, but moxifloxacin therapy was begun while awaiting culture results because empirical antifungal therapy is not recommended. Although it is our routine to initiate "fortified" antibiotic therapy for moderate to severe bacterial keratitis, monotherapy with a fluoroquinolone may be used pending identification of the pathogen for indolent or small infiltrates, or, based on clinical experience, for infiltrate with features suggestive of fungal infection.
The current cases suggest that initial improvement on antibiotic therapy should not lead to the assumption that the patient has bacterial keratitis. Close follow-up should be maintained and one should be aware of the possibility that the patient may have a partially responsive fungal keratitis that may ultimately be inadequately treated by antibiotics alone.
In general, corticosteroid therapy should be withheld until the infecting organism has been identified. 
